Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
The chart shows the growth of an initial investment of $10,000 in Allogene Therapeutics, Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Allogene Therapeutics, Inc. Common Stock (ALLO) has returned 79.71% so far this year and 75.89% over the past 12 months. Looking at the last ten years, ALLO has achieved an annualized return of -19.61%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Allogene Therapeutics, Inc. Common Stock (ALLO) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 33.33% | 53.59% | -7.22% | -0.80% | ||||||||
| 2025 | -17.05% | 9.55% | -21.08% | 16.67% | -29.94% | -5.04% | 8.85% | -7.76% | 7.83% | 16.80% | -4.86% | |
| 2024 | 10.34% | 38.31% | -9.51% | -37.70% | -10.07% | -7.91% | 26.18% | -10.85% | 8.53% | -7.43% | -3.50% | -14.11% |
| 2023 | 19.50% | -17.64% | -26.71% | 9.92% | -2.78% | -5.15% | 0.40% | -21.41% | -18.72% | -11.32% | -16.07% | 37.18% |
| 2022 | -23.41% | -20.57% | 0.55% | -9.24% | -4.23% | 43.58% | 14.16% | 6.94% | -21.11% | -7.04% | -6.36% | -36.01% |
| 2021 | 32.80% | -0.80% | -1.53% | -11.66% | -14.90% | 1.76% | -15.67% | 8.02% | 8.16% | -32.42% | 8.51% | -18.29% |
| 2020 | -16.27% | 24.54% | -27.65% | 52.27% | 70.96% | -7.16% | -12.57% | -2.30% | 5.78% | -10.12% | -8.68% | -19.02% |
| 2019 | 13.94% | 4.35% | -9.94% | 2.71% | -11.95% | -0.19% | 16.06% | -12.16% | 1.66% | 6.04% | -1.19% | -7.38% |
| 2018 | 9.14% | 28.57% | -15.61% |
The charts below present risk-adjusted performance metrics for Allogene Therapeutics, Inc. Common Stock (ALLO) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ALLO compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Allogene Therapeutics, Inc. Common Stock volatility is 7.02%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 415.91M | 548.71M | 642.84M | 817.08M | 1.04B | 1.23B | 717.80M | 773.86M |
| Equity Attributable To Parent (USD) | 292.54M | 422.18M | 512.23M | 665.87M | 916.41M | 1.08B | 629.02M | 703.16M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - |
| Equity (USD) | 292.54M | 422.18M | 512.23M | 665.87M | 916.41M | 1.08B | 629.02M | 703.16M |
| Noncurrent Liabilities (USD) | 90.85M | 91.01M | 93.53M | 96.69M | 74.05M | 53.89M | 55.70M | 41.23M |
| Other Current Liabilities (USD) | 18.00M | 17.98M | 18.52M | 22.69M | 37.92M | 83.93M | 23.83M | 17.12M |
| Wages (USD) | 10.24M | 12.15M | 12.67M | 17.94M | - | - | - | - |
| Accounts Payable (USD) | 4.27M | 5.39M | 5.90M | 13.89M | 10.26M | 10.39M | 9.25M | 12.34M |
| Current Liabilities (USD) | 32.51M | 35.52M | 37.08M | 54.52M | 48.17M | 94.32M | 33.08M | 29.46M |
| Liabilities (USD) | 123.36M | 126.53M | 130.60M | 151.21M | 122.23M | 148.21M | 88.78M | 70.69M |
| Other Non-current Assets (USD) | 85.32M | 159.27M | 84.24M | 175.42M | 444.32M | 263.86M | 116.63M | 296.52M |
| Intangible Assets (USD) | - | - | - | - | - | - | 151.00K | 754.00K |
| Fixed Assets (USD) | 72.84M | 86.06M | 99.48M | 112.84M | 122.99M | 118.84M | 56.45M | 8.60M |
| Noncurrent Assets (USD) | 158.16M | 245.32M | 183.72M | 288.26M | 567.31M | 382.70M | 173.23M | 305.87M |
| Other Current Assets (USD) | - | - | 10.42M | - | - | - | - | - |
| Cash (USD) | 258.30M | 373.10M | 448.70M | 576.50M | 809.50M | 1.00B | 588.90M | 721.40M |
| Current Assets (USD) | 257.75M | 303.39M | 459.12M | 528.82M | 471.32M | 845.13M | 544.58M | 467.98M |
| Assets (USD) | 415.91M | 548.71M | 642.84M | 817.08M | 1.04B | 1.23B | 717.80M | 773.86M |
Allogene Therapeutics won an arbitration against Cellectis regarding CAR-T therapy development rights, securing full control of cemacabtagene ansegedleucel in the U.S., EU, and U.K., while the tribunal rejected Cellectis's financial claims and allegations.
Allogene Therapeutics won a favorable arbitration ruling with Cellectis, reconfirming full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the US, EU, and UK, with a path to acquire full global rights by 2026.
The U.S. CAR T-cell therapies market is expected to grow from USD 3.43 billion in 2026 to USD 42.61 billion by 2035, driven by rising cancer cases, research investments, and innovative therapeutic approaches.
Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.
Allogene Therapeutics presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma, showing promising results with a 31% confirmed response rate and durable responses in heavily pretreated patients.
The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.
The oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.
The gene therapy market is experiencing significant growth, with over 180 companies actively developing more than 200 gene therapies. This dynamic landscape highlights the increasing investment and innovation in the sector, promising new treatment options for various diseases.
The gene editing therapeutics market is expected to grow significantly, reaching $1 billion by 2029 with a CAGR of 147%. Key drivers include the increasing prevalence of chronic and rare genetic diseases, as well as the need for precision medicine.
SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that Rocky Mountain Cancer Centers (RMCC), part of the US Oncology Network and Sarah Cannon Research Institute (SCRI); Astera Cancer Care (ACC), a multi-specialty community oncology practice and part of the OneOncology network; and Norton Cancer Institute, are open for enrollment in the pivotal Phase 2 ALPHA3 trial.